SUTENT is also approved for both gastrointestinal stromal tumors
(GIST) after disease progression on or intolerance to imatinib mesylate, and advanced renal cell carcinoma (RCC) in over 100 countries and has been studied in over 10,000 patients in clinical trials.
This panel should be used most commonly in daily practice to aid in identification of gastrointestinal stromal tumor
, leiomyosarcoma, and schwannoma.
This protocol applies to gastrointestinal stromal tumor
Although a variety of mesenchymal tumors may occur in the anal canal, such as smooth muscle tumors, gastrointestinal stromal tumors
(GISTs), schwannomas, sarcomas related to endometriosis or the miillerian system, and lymphagiomas, (67) the most commonly seen are smooth muscle tumors and GISTs.
Food and Drug Administration (FDA) in January 2006 for the treatment of gastrointestinal stromal tumor
after disease progression or intolerance to imatinib mesylate and advanced renal cell carcinoma.
The poster communication "Masitinib in comparison to imatinib as first line therapy of patients with advanced gastrointestinal stromal tumor
(GIST): A randomized phase III trial", delivered by Professor Antoine Adenis (Centre Oscar Lambret, Lille, France), reported on the progress and characteristics of this phase III study.
Presence of homozygous KIT exon 11 mutation is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors
CD34 was advocated as a more reproducible marker of gastrointestinal stromal tumors
Read the full report: Gastrointestinal Stromal Tumor
(GIST) Global Clinical Trials Review, H1, 2014 http://www.
A gastrointestinal stromal tumor
(GIST) is a type of cancer that occurs in the gastrointestinal (GI or digestive) tract, including the esophagus, stomach, gallbladder, liver, small intestine, colon, and rectum.
The differential diagnosis of benign fibroblastic polyps includes other spindle cell proliferations that may present as mucosal polyps within the gastrointestinal tract, including inflammatory fibroid polyps (Vanek tumor), gastrointestinal stromal tumor
, schwannoma, ganglioneuroma, inflammatory cloacogenic polyp, prolapsing mucosal polyp, smooth muscle tumors, and the recently described intestinal perineurioma.
Exposure-efficacy analysis of regorafenib (REG) and its metabolites M-2 and M-5 in the phase III GRID study in patients (pts) with metastatic gastrointestinal stromal tumor